As a high-quality supplier of microarray chips, CD Genomics is committed to providing various solutions for oncology-related research, including a full range of microarray tools and professional testing services. Our microarray platform provides a variety of products such as DNA microarrays, protein microarrays, antibody microarrays, chemical microarrays and tissue arrays for the study of tumor molecular mechanisms, covering a variety of solid tumors and hematological tumors. With our time-tested capabilities and expertise, we are confident to remove obstacles to your research path.
The development of cancer biology leaves the development of molecular detection technology. The application of microarray technology in this area predates other technologies such as next-generation sequencing (NGS). The earliest developed DNA microarray products were used to analyze tumor genes and regions of interest. In the field of cancer biology research, the early applications of microarrays mainly focused on identifying differences in gene expression between tumor cells and normal cells, from the genome to the transcriptome. The development at this stage has also promoted the development of bioinformatics related to microarray data analysis. Our convenient and high-efficiency microarray products and services cover all the hot spots of current tumor biology research. The microarray detection method can be used to obtain high-throughput data of cancer cell gene expression changes, including transcriptome data and non-coding RNA expression related data. These data are of great significance for understanding tumorigenesis. In recent years, the role of epigenetics in tumorigenesis and development has attracted more and more attention, and many methylation microarrays have been used for correlation analysis. At the same time, the demand for detailed clinical diagnosis of tumors has promoted the application of genotyping microarrays. In addition, a large number of antibody microarrays can be used to analyze tumor-related signal pathways. For the detection of end-products of gene expression, tissue microarray is also an indispensable helper.
In oncology research, the application of microarray technology provides a shortcut for extensively extracting biomedical-related data. This effective method will provide high-throughput and valuable insights to help researchers understand differences in DNA, mRNA expression, protein expression and activity related to tumor formation. The tumor is a complex disease with individualization and heterogeneity. Its occurrence and development are closely related to genetic changes. These characteristics also emphasize the importance of tumor research with personalized medicine as the core. The "molecular disease classification" of cancer is achieved by comparing tumor-related and tumor-specific biomarkers formed by differences in tissue-specific disease characteristics between individuals. The development of genomic microarrays (DNA microarrays) has made it convenient to monitor tens of thousands of genes at the same time to study their expression changes in tumor and non-tumor tissues. This helps to detect meaningful patterns in complex gene expression patterns in cancer research, and use microarray methods to analyze gene expression patterns that initiate or maintain the cancer-causing state of cancer cells. In personalized research, the accumulation of genetic and epigenetic events can also directly or indirectly lead to malignant transformation. Epigenetic microarray products are highly efficient for analyzing the methylation events of DNA, RNA and histones. Our epigenetics microarrays include these products. Of course, for understanding the events of gene expression regulation, an indispensable part is the phosphorylation event of the signal pathway, which can be detected by phosphorylation antibody microarray for high-throughput detection. The high-throughput characteristics of microarrays are essential for understanding the complexity and polymorphism of cancer in functional research.
Fig. 1 Microarray products covering all aspects of tumor and research.
Product-based testing services facilitate global cancer testing. We have established a complete microarray testing laboratory platform that can process cancer samples from humans and animals. Our DNA microarray platform can realize copy number analysis, genotyping, CGH analysis, transcriptomics analysis, etc. with nucleic acid as the target detection. At the same time, our protein/antibody microarray platform can realize the analysis of protein components in liquid samples, which is based on diversified antibody microarray, cytokine microarray and peptide microarray products. In addition to monitoring gene expression patterns, our microarray platform also provides methylated microarray products that can decode the epigenome of multiple types of cancer cells. Finally, our laboratory also has an independent histological analysis platform that provides multi-tumor tissue arrays for analyzing multiple protein targets.
Generally, CD Genomics's microarray platform can help customers understand the genetic and epigenetic composition of cancer cells in the process of cancer research. The completion of these tasks is also inseparable from the in-depth analysis of data in bioinformatics. Our microarray service platform can help customers maximize the use of data obtained from a single test. If your cancer biology project requires related microarray testing, please contact us .